{"id":"mdm2","name":"MDM2","symbol":"MDM2","route":"/targets/mdm2/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6973","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135679","uniprot":"https://www.uniprot.org/uniprotkb/Q00987/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q00987","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5023","open-targets":"https://platform.opentargets.org/target/ENSG00000135679","civic":"https://civicdb.org/genes/4193/summary","oncokb":"https://www.oncokb.org/gene/MDM2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MDM2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MDM2","depmap":"https://depmap.org/portal/gene/MDM2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000135679-MDM2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4193","omim":"https://www.omim.org/entry/164785"}],"products":[{"id":"brigimadlin","name":"Brigimadlin","status":"phase-3","modality":"Oral MDM2-p53 antagonist","route":"/drugs/brigimadlin/"},{"id":"krt-232","name":"KRT-232","status":"phase-2","modality":"small molecule","route":"/drugs/krt-232/"}],"trials":[{"id":"nct05797831","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","nct":"NCT05797831","phase":"2/3","status":"recruiting"},{"id":"nct06619509","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","nct":"NCT06619509","phase":"2","status":"active"},{"id":"nct03669965","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","nct":"NCT03669965","phase":"2","status":"active"},{"id":"nct04502394","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","nct":"NCT04502394","phase":"1/2","status":"recruiting"},{"id":"nct06578624","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","nct":"NCT06578624","phase":"1/2","status":"recruiting"}],"pathways":["bladder-cancer-signalling","glioma-signalling","melanoma-signalling","prostate-cancer-signalling","p53-mdm2-axis","ubiquitin-proteasome-system"],"companies":["boehringer-ingelheim","kartos-therapeutics"],"keyPapers":["paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","paper-barretina-nat-genet","paper-vogelstein-surfing-p53-network-nature-2000","paper-levine-p53-gatekeeper-cell-1997"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}